img

Global Primary Immunodeficiency Therapeutic Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Primary Immunodeficiency Therapeutic Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

Primary immunodeficiencies are a group of different disorders in which part of the body's immune system (mainly cells and proteins) is missing or does not function normally. As per researchers, estimated more than 300 different kinds of primary immunodeficiency disease (PIDD). The immune system is composed of white blood cells made in the bone marrow which protect and defend against attacks by foreign invaders such as bacteria, fungi, and germs. Antibodies and Complement are proteins that are made in response to infection or immunization and helps to fight against infections and plays a protective role in the immune system. In the most common primary immunodeficiency diseases, different forms of cells or proteins are missing or do not function which results in severe infections and/or infections that are unusually hard to cure. These infections may attack the respiratory system, the brain or spinal cord, the ears, skin, or in the urinary or gastrointestinal tracts. In some instances, primary immunodeficiency diseases target specific and/or multiple organs, glands, cells, and tissues. For example, heart defects are present in some primary immunodeficiency diseases.
Primary Immunodeficiency Therapeutic report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Primary Immunodeficiency Therapeutic market is projected to reach US$ 669.8 million in 2029, increasing from US$ 459 million in 2022, with the CAGR of 5.6% during the period of 2024 to 2029. Demand from Antibody Deficiency and Cellular Immunodeficiency are the major drivers for the industry.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Primary Immunodeficiency Therapeutic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report



By Company


Baxter International
Takeda Pharmaceutical
CSL Limited
Octapharma
Kedrion Biopharma
Bio Products Laboratory
LFB group
Grifols
Lupin Pharmaceuticals
Segment by Type
Immunoglobulin Replacement Therapy
Stem Cell or Bone Marrow Transplantation
Antibiotic Therapy
Gene Therapy
Others

Segment by Application


Antibody Deficiency
Cellular Immunodeficiency
Innate Immune Disorders
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia

Latin America
Mexico
Brazil

Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Primary Immunodeficiency Therapeutic market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Primary Immunodeficiency Therapeutic introduction, etc. Primary Immunodeficiency Therapeutic Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Primary Immunodeficiency Therapeutic market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Market Overview of Primary Immunodeficiency Therapeutic
1.1 Primary Immunodeficiency Therapeutic Market Overview
1.1.1 Primary Immunodeficiency Therapeutic Product Scope
1.1.2 Primary Immunodeficiency Therapeutic Market Status and Outlook
1.2 Global Primary Immunodeficiency Therapeutic Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Primary Immunodeficiency Therapeutic Market Size by Region (2018-2029)
1.4 Global Primary Immunodeficiency Therapeutic Historic Market Size by Region (2018-2024)
1.5 Global Primary Immunodeficiency Therapeutic Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Primary Immunodeficiency Therapeutic Market Size (2018-2029)
1.6.1 North America Primary Immunodeficiency Therapeutic Market Size (2018-2029)
1.6.2 Europe Primary Immunodeficiency Therapeutic Market Size (2018-2029)
1.6.3 Asia-Pacific Primary Immunodeficiency Therapeutic Market Size (2018-2029)
1.6.4 Latin America Primary Immunodeficiency Therapeutic Market Size (2018-2029)
1.6.5 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size (2018-2029)
2 Primary Immunodeficiency Therapeutic Market by Type
2.1 Introduction
2.1.1 Immunoglobulin Replacement Therapy
2.1.2 Stem Cell or Bone Marrow Transplantation
2.1.3 Antibiotic Therapy
2.1.4 Gene Therapy
2.1.5 Others
2.2 Global Primary Immunodeficiency Therapeutic Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Primary Immunodeficiency Therapeutic Historic Market Size by Type (2018-2024)
2.2.2 Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Primary Immunodeficiency Therapeutic Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Primary Immunodeficiency Therapeutic Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Primary Immunodeficiency Therapeutic Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Primary Immunodeficiency Therapeutic Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Primary Immunodeficiency Therapeutic Revenue Breakdown by Type (2018-2029)
3 Primary Immunodeficiency Therapeutic Market Overview by Application
3.1 Introduction
3.1.1 Antibody Deficiency
3.1.2 Cellular Immunodeficiency
3.1.3 Innate Immune Disorders
3.1.4 Others
3.2 Global Primary Immunodeficiency Therapeutic Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Primary Immunodeficiency Therapeutic Historic Market Size by Application (2018-2024)
3.2.2 Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Primary Immunodeficiency Therapeutic Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Primary Immunodeficiency Therapeutic Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Primary Immunodeficiency Therapeutic Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Primary Immunodeficiency Therapeutic Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Primary Immunodeficiency Therapeutic Revenue Breakdown by Application (2018-2029)
4 Primary Immunodeficiency Therapeutic Competition Analysis by Players
4.1 Global Primary Immunodeficiency Therapeutic Market Size by Players (2018-2024)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Primary Immunodeficiency Therapeutic as of 2022)
4.3 Date of Key Players Enter into Primary Immunodeficiency Therapeutic Market
4.4 Global Top Players Primary Immunodeficiency Therapeutic Headquarters and Area Served
4.5 Key Players Primary Immunodeficiency Therapeutic Product Solution and Service
4.6 Competitive Status
4.6.1 Primary Immunodeficiency Therapeutic Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Baxter International
5.1.1 Baxter International Profile
5.1.2 Baxter International Main Business
5.1.3 Baxter International Primary Immunodeficiency Therapeutic Products, Services and Solutions
5.1.4 Baxter International Primary Immunodeficiency Therapeutic Revenue (US$ Million) & (2018-2024)
5.1.5 Baxter International Recent Developments
5.2 Takeda Pharmaceutical
5.2.1 Takeda Pharmaceutical Profile
5.2.2 Takeda Pharmaceutical Main Business
5.2.3 Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Products, Services and Solutions
5.2.4 Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Revenue (US$ Million) & (2018-2024)
5.2.5 Takeda Pharmaceutical Recent Developments
5.3 CSL Limited
5.3.1 CSL Limited Profile
5.3.2 CSL Limited Main Business
5.3.3 CSL Limited Primary Immunodeficiency Therapeutic Products, Services and Solutions
5.3.4 CSL Limited Primary Immunodeficiency Therapeutic Revenue (US$ Million) & (2018-2024)
5.3.5 Octapharma Recent Developments
5.4 Octapharma
5.4.1 Octapharma Profile
5.4.2 Octapharma Main Business
5.4.3 Octapharma Primary Immunodeficiency Therapeutic Products, Services and Solutions
5.4.4 Octapharma Primary Immunodeficiency Therapeutic Revenue (US$ Million) & (2018-2024)
5.4.5 Octapharma Recent Developments
5.5 Kedrion Biopharma
5.5.1 Kedrion Biopharma Profile
5.5.2 Kedrion Biopharma Main Business
5.5.3 Kedrion Biopharma Primary Immunodeficiency Therapeutic Products, Services and Solutions
5.5.4 Kedrion Biopharma Primary Immunodeficiency Therapeutic Revenue (US$ Million) & (2018-2024)
5.5.5 Kedrion Biopharma Recent Developments
5.6 Bio Products Laboratory
5.6.1 Bio Products Laboratory Profile
5.6.2 Bio Products Laboratory Main Business
5.6.3 Bio Products Laboratory Primary Immunodeficiency Therapeutic Products, Services and Solutions
5.6.4 Bio Products Laboratory Primary Immunodeficiency Therapeutic Revenue (US$ Million) & (2018-2024)
5.6.5 Bio Products Laboratory Recent Developments
5.7 LFB group
5.7.1 LFB group Profile
5.7.2 LFB group Main Business
5.7.3 LFB group Primary Immunodeficiency Therapeutic Products, Services and Solutions
5.7.4 LFB group Primary Immunodeficiency Therapeutic Revenue (US$ Million) & (2018-2024)
5.7.5 LFB group Recent Developments
5.8 Grifols
5.8.1 Grifols Profile
5.8.2 Grifols Main Business
5.8.3 Grifols Primary Immunodeficiency Therapeutic Products, Services and Solutions
5.8.4 Grifols Primary Immunodeficiency Therapeutic Revenue (US$ Million) & (2018-2024)
5.8.5 Grifols Recent Developments
5.9 Lupin Pharmaceuticals
5.9.1 Lupin Pharmaceuticals Profile
5.9.2 Lupin Pharmaceuticals Main Business
5.9.3 Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Products, Services and Solutions
5.9.4 Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Revenue (US$ Million) & (2018-2024)
5.9.5 Lupin Pharmaceuticals Recent Developments
6 North America
6.1 North America Primary Immunodeficiency Therapeutic Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Primary Immunodeficiency Therapeutic Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Primary Immunodeficiency Therapeutic Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Primary Immunodeficiency Therapeutic Market Dynamics
11.1 Primary Immunodeficiency Therapeutic Industry Trends
11.2 Primary Immunodeficiency Therapeutic Market Drivers
11.3 Primary Immunodeficiency Therapeutic Market Challenges
11.4 Primary Immunodeficiency Therapeutic Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Primary Immunodeficiency Therapeutic Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2029
Table 2. Global Primary Immunodeficiency Therapeutic Market Size by Region (2018-2024) & (US$ Million)
Table 3. Global Primary Immunodeficiency Therapeutic Market Size Share by Region (2018-2024)
Table 4. Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 5. Global Primary Immunodeficiency Therapeutic Forecasted Market Size Share by Region (2024-2029)
Table 6. Global Primary Immunodeficiency Therapeutic Market Size (US$ Million) by Type: 2018 VS 2022 VS 2029
Table 7. Global Primary Immunodeficiency Therapeutic Market Size by Type (2018-2024) & (US$ Million)
Table 8. Global Primary Immunodeficiency Therapeutic Revenue Market Share by Type (2018-2024)
Table 9. Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 10. Global Primary Immunodeficiency Therapeutic Revenue Market Share by Type (2024-2029)
Table 11. North America Primary Immunodeficiency Therapeutic Revenue by Type (2018-2024) & (US$ Million)
Table 12. North America Primary Immunodeficiency Therapeutic Revenue by Type (2024-2029) & (US$ Million)
Table 13. Europe Primary Immunodeficiency Therapeutic Revenue by Type (2018-2024) & (US$ Million)
Table 14. Europe Primary Immunodeficiency Therapeutic Revenue by Type (2024-2029) & (US$ Million)
Table 15. Asia-Pacific Primary Immunodeficiency Therapeutic Revenue by Type (2018-2024) & (US$ Million)
Table 16. Asia-Pacific Primary Immunodeficiency Therapeutic Revenue by Type (2024-2029) & (US$ Million)
Table 17. Latin America Primary Immunodeficiency Therapeutic Revenue by Type (2018-2024) & (US$ Million)
Table 18. Latin America Primary Immunodeficiency Therapeutic Revenue by Type (2024-2029) & (US$ Million)
Table 19. Middle East and Africa Primary Immunodeficiency Therapeutic Revenue by Type (2018-2024) & (US$ Million)
Table 20. Middle East and Africa Primary Immunodeficiency Therapeutic Revenue by Type (2024-2029) & (US$ Million)
Table 21. Global Primary Immunodeficiency Therapeutic Market Size (US$ Million) by Application: 2018 VS 2022 VS 2029
Table 22. Global Primary Immunodeficiency Therapeutic Market Size by Application (2018-2024) & (US$ Million)
Table 23. Global Primary Immunodeficiency Therapeutic Revenue Market Share by Application (2018-2024)
Table 24. Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 25. Global Primary Immunodeficiency Therapeutic Revenue Market Share by Application (2024-2029)
Table 26. North America Primary Immunodeficiency Therapeutic Revenue by Application (2018-2024) & (US$ Million)
Table 27. North America Primary Immunodeficiency Therapeutic Revenue by Application (2024-2029) & (US$ Million)
Table 28. Europe Primary Immunodeficiency Therapeutic Revenue by Application (2018-2024) & (US$ Million)
Table 29. Europe Primary Immunodeficiency Therapeutic Revenue by Application (2024-2029) & (US$ Million)
Table 30. Asia-Pacific Primary Immunodeficiency Therapeutic Revenue by Application (2018-2024) & (US$ Million)
Table 31. Asia-Pacific Primary Immunodeficiency Therapeutic Revenue by Application (2024-2029) & (US$ Million)
Table 32. Latin America Primary Immunodeficiency Therapeutic Revenue by Application (2018-2024) & (US$ Million)
Table 33. Latin America Primary Immunodeficiency Therapeutic Revenue by Application (2024-2029) & (US$ Million)
Table 34. Middle East and Africa Primary Immunodeficiency Therapeutic Revenue by Application (2018-2024) & (US$ Million)
Table 35. Middle East and Africa Primary Immunodeficiency Therapeutic Revenue by Application (2024-2029) & (US$ Million)
Table 36. Global Primary Immunodeficiency Therapeutic Revenue (US$ Million) by Players (2018-2024)
Table 37. Global Primary Immunodeficiency Therapeutic Revenue Market Share by Players (2018-2024)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Primary Immunodeficiency Therapeutic as of 2022)
Table 39. Date of Key Players Enter into Primary Immunodeficiency Therapeutic Market
Table 40. Global Primary Immunodeficiency Therapeutic Key Players Headquarters and Area Served
Table 41. Primary Immunodeficiency Therapeutic Product Solution and Service
Table 42. Global Primary Immunodeficiency Therapeutic Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Baxter International Basic Information List
Table 45. Baxter International Description and Business Overview
Table 46. Baxter International Primary Immunodeficiency Therapeutic Products, Services and Solutions
Table 47. Revenue (US$ Million) in Primary Immunodeficiency Therapeutic Business of Baxter International (2018-2024)
Table 48. Baxter International Recent Developments
Table 49. Takeda Pharmaceutical Basic Information List
Table 50. Takeda Pharmaceutical Description and Business Overview
Table 51. Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Products, Services and Solutions
Table 52. Revenue (US$ Million) in Primary Immunodeficiency Therapeutic Business of Takeda Pharmaceutical (2018-2024)
Table 53. Takeda Pharmaceutical Recent Developments
Table 54. CSL Limited Basic Information List
Table 55. CSL Limited Description and Business Overview
Table 56. CSL Limited Primary Immunodeficiency Therapeutic Products, Services and Solutions
Table 57. Revenue (US$ Million) in Primary Immunodeficiency Therapeutic Business of CSL Limited (2018-2024)
Table 58. CSL Limited Recent Developments
Table 59. Octapharma Basic Information List
Table 60. Octapharma Description and Business Overview
Table 61. Octapharma Primary Immunodeficiency Therapeutic Products, Services and Solutions
Table 62. Revenue (US$ Million) in Primary Immunodeficiency Therapeutic Business of Octapharma (2018-2024)
Table 63. Octapharma Recent Developments
Table 64. Kedrion Biopharma Basic Information List
Table 65. Kedrion Biopharma Description and Business Overview
Table 66. Kedrion Biopharma Primary Immunodeficiency Therapeutic Products, Services and Solutions
Table 67. Revenue (US$ Million) in Primary Immunodeficiency Therapeutic Business of Kedrion Biopharma (2018-2024)
Table 68. Kedrion Biopharma Recent Developments
Table 69. Bio Products Laboratory Basic Information List
Table 70. Bio Products Laboratory Description and Business Overview
Table 71. Bio Products Laboratory Primary Immunodeficiency Therapeutic Products, Services and Solutions
Table 72. Revenue (US$ Million) in Primary Immunodeficiency Therapeutic Business of Bio Products Laboratory (2018-2024)
Table 73. Bio Products Laboratory Recent Developments
Table 74. LFB group Basic Information List
Table 75. LFB group Description and Business Overview
Table 76. LFB group Primary Immunodeficiency Therapeutic Products, Services and Solutions
Table 77. Revenue (US$ Million) in Primary Immunodeficiency Therapeutic Business of LFB group (2018-2024)
Table 78. LFB group Recent Developments
Table 79. Grifols Basic Information List
Table 80. Grifols Description and Business Overview
Table 81. Grifols Primary Immunodeficiency Therapeutic Products, Services and Solutions
Table 82. Revenue (US$ Million) in Primary Immunodeficiency Therapeutic Business of Grifols (2018-2024)
Table 83. Grifols Recent Developments
Table 84. Lupin Pharmaceuticals Basic Information List
Table 85. Lupin Pharmaceuticals Description and Business Overview
Table 86. Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Products, Services and Solutions
Table 87. Revenue (US$ Million) in Primary Immunodeficiency Therapeutic Business of Lupin Pharmaceuticals (2018-2024)
Table 88. Lupin Pharmaceuticals Recent Developments
Table 89. North America Primary Immunodeficiency Therapeutic Market Size by Country (2018-2024) & (US$ Million)
Table 90. North America Primary Immunodeficiency Therapeutic Market Size by Country (2024-2029) & (US$ Million)
Table 91. Europe Primary Immunodeficiency Therapeutic Market Size by Country (2018-2024) & (US$ Million)
Table 92. Europe Primary Immunodeficiency Therapeutic Market Size by Country (2024-2029) & (US$ Million)
Table 93. Asia-Pacific Primary Immunodeficiency Therapeutic Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 94. Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Region (2018-2024) & (US$ Million)
Table 95. Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Region (2024-2029) & (US$ Million)
Table 96. Asia-Pacific Primary Immunodeficiency Therapeutic Market Share by Region (2018-2024)
Table 97. Asia-Pacific Primary Immunodeficiency Therapeutic Market Share by Region (2024-2029)
Table 98. Latin America Primary Immunodeficiency Therapeutic Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 99. Latin America Primary Immunodeficiency Therapeutic Market Size by Country (2018-2024) & (US$ Million)
Table 100. Latin America Primary Immunodeficiency Therapeutic Market Size by Country (2024-2029) & (US$ Million)
Table 101. Middle East & Africa Primary Immunodeficiency Therapeutic Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 102. Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Country (2018-2024) & (US$ Million)
Table 103. Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Country (2024-2029) & (US$ Million)
Table 104. Primary Immunodeficiency Therapeutic Market Trends
Table 105. Primary Immunodeficiency Therapeutic Market Drivers
Table 106. Primary Immunodeficiency Therapeutic Market Challenges
Table 107. Primary Immunodeficiency Therapeutic Market Restraints
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Primary Immunodeficiency Therapeutic Market Size Year-over-Year 2018-2029 & (US$ Million)
Figure 2. Global Primary Immunodeficiency Therapeutic Market Size (US$ Million), 2018 VS 2022 VS 2029
Figure 3. Global Primary Immunodeficiency Therapeutic Market Share by Regions: 2022 VS 2029
Figure 4. Global Primary Immunodeficiency Therapeutic Forecasted Market Size Share by Region (2024-2029)
Figure 5. North America Primary Immunodeficiency Therapeutic Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 6. Europe Primary Immunodeficiency Therapeutic Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 7. Asia-Pacific Primary Immunodeficiency Therapeutic Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 8. Latin America Primary Immunodeficiency Therapeutic Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 9. Middle East & Africa Primary Immunodeficiency Therapeutic Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 10. Product Picture of Immunoglobulin Replacement Therapy
Figure 11. Global Immunoglobulin Replacement Therapy Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 12. Product Picture of Stem Cell or Bone Marrow Transplantation
Figure 13. Global Stem Cell or Bone Marrow Transplantation Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 14. Product Picture of Antibiotic Therapy
Figure 15. Global Antibiotic Therapy Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 16. Product Picture of Gene Therapy
Figure 17. Global Gene Therapy Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 18. Product Picture of Others
Figure 19. Global Others Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 20. Global Primary Immunodeficiency Therapeutic Market Size Share by Type: 2022 & 2029
Figure 21. North America Primary Immunodeficiency Therapeutic Revenue Market Share by Type (2018-2029)
Figure 22. Europe Primary Immunodeficiency Therapeutic Revenue Market Share by Type (2018-2029)
Figure 23. Asia-Pacific Primary Immunodeficiency Therapeutic Revenue Market Share by Type (2018-2029)
Figure 24. Latin America Primary Immunodeficiency Therapeutic Revenue Market Share by Type (2018-2029)
Figure 25. Middle East and Africa Primary Immunodeficiency Therapeutic Revenue Market Share by Type (2018-2029)
Figure 26. Antibody Deficiency Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 27. Cellular Immunodeficiency Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 28. Innate Immune Disorders Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 29. Others Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 30. Global Primary Immunodeficiency Therapeutic Market Size Share by Application: 2022 & 2029
Figure 31. North America Primary Immunodeficiency Therapeutic Revenue Market Share by Application (2018-2029)
Figure 32. Europe Primary Immunodeficiency Therapeutic Revenue Market Share by Application (2018-2029)
Figure 33. Asia-Pacific Primary Immunodeficiency Therapeutic Revenue Market Share by Application (2018-2029)
Figure 34. Latin America Primary Immunodeficiency Therapeutic Revenue Market Share by Application (2018-2029)
Figure 35. Middle East and Africa Primary Immunodeficiency Therapeutic Revenue Market Share by Application (2018-2029)
Figure 36. Primary Immunodeficiency Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 37. Global Top 5 and Top 10 Players Primary Immunodeficiency Therapeutic Market Share in 2022
Figure 38. North America Primary Immunodeficiency Therapeutic Market Share by Country (2018-2029)
Figure 39. United States Primary Immunodeficiency Therapeutic Market Size (2018-2029) & (US$ Million)
Figure 40. Canada Primary Immunodeficiency Therapeutic Market Size (2018-2029) & (US$ Million)
Figure 41. Germany Primary Immunodeficiency Therapeutic Market Size (2018-2029) & (US$ Million)
Figure 42. France Primary Immunodeficiency Therapeutic Market Size (2018-2029) & (US$ Million)
Figure 43. U.K. Primary Immunodeficiency Therapeutic Market Size (2018-2029) & (US$ Million)
Figure 44. Italy Primary Immunodeficiency Therapeutic Market Size (2018-2029) & (US$ Million)
Figure 45. Russia Primary Immunodeficiency Therapeutic Market Size (2018-2029) & (US$ Million)
Figure 46. Nordic Countries Primary Immunodeficiency Therapeutic Market Size (2018-2029) & (US$ Million)
Figure 47. Asia-Pacific Primary Immunodeficiency Therapeutic Market Share by Region (2018-2029)
Figure 48. China Primary Immunodeficiency Therapeutic Market Size (2018-2029) & (US$ Million)
Figure 49. Japan Primary Immunodeficiency Therapeutic Market Size (2018-2029) & (US$ Million)
Figure 50. South Korea Primary Immunodeficiency Therapeutic Market Size (2018-2029) & (US$ Million)
Figure 51. Southeast Asia Primary Immunodeficiency Therapeutic Market Size (2018-2029) & (US$ Million)
Figure 52. India Primary Immunodeficiency Therapeutic Market Size (2018-2029) & (US$ Million)
Figure 53. Australia Primary Immunodeficiency Therapeutic Market Size (2018-2029) & (US$ Million)
Figure 54. Latin America Primary Immunodeficiency Therapeutic Market Share by Country (2018-2029)
Figure 55. Mexico Primary Immunodeficiency Therapeutic Market Size (2018-2029) & (US$ Million)
Figure 56. Brazil Primary Immunodeficiency Therapeutic Market Size (2018-2029) & (US$ Million)
Figure 57. Middle East & Africa Primary Immunodeficiency Therapeutic Market Share by Country (2018-2029)
Figure 58. Turkey Primary Immunodeficiency Therapeutic Market Size (2018-2029) & (US$ Million)
Figure 59. Saudi Arabia Primary Immunodeficiency Therapeutic Market Size (2018-2029) & (US$ Million)
Figure 60. UAE Primary Immunodeficiency Therapeutic Market Size (2018-2029) & (US$ Million)
Figure 61. Bottom-up and Top-down Approaches for This Report

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries